ID29927A - Senyawa-senyawa triazolo (4,5-d) pirimidin baru - Google Patents

Senyawa-senyawa triazolo (4,5-d) pirimidin baru

Info

Publication number
ID29927A
ID29927A IDW00200101173A ID20011173A ID29927A ID 29927 A ID29927 A ID 29927A ID W00200101173 A IDW00200101173 A ID W00200101173A ID 20011173 A ID20011173 A ID 20011173A ID 29927 A ID29927 A ID 29927A
Authority
ID
Indonesia
Prior art keywords
triazolo compounds
pyrimidin
new
new pyrimidin
triazolo
Prior art date
Application number
IDW00200101173A
Other languages
English (en)
Indonesian (id)
Inventor
Simon Guile
David Hardern
Anthony Ingall
Brian Springthorpe
Paul Willis
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26663448&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ID29927(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from SE9804211A external-priority patent/SE9804211D0/xx
Priority claimed from SE9901271A external-priority patent/SE9901271D0/xx
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of ID29927A publication Critical patent/ID29927A/id

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/39—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
    • C07C211/40—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing only non-condensed rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
IDW00200101173A 1998-12-04 1999-12-02 Senyawa-senyawa triazolo (4,5-d) pirimidin baru ID29927A (id)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9804211A SE9804211D0 (sv) 1998-12-04 1998-12-04 Novel compounds
SE9901271A SE9901271D0 (sv) 1999-04-09 1999-04-09 Novel compounds

Publications (1)

Publication Number Publication Date
ID29927A true ID29927A (id) 2001-10-25

Family

ID=26663448

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW00200101173A ID29927A (id) 1998-12-04 1999-12-02 Senyawa-senyawa triazolo (4,5-d) pirimidin baru

Country Status (36)

Country Link
US (12) US6525060B1 (es)
EP (5) EP1386917B1 (es)
JP (4) JP4202607B2 (es)
KR (4) KR100764417B1 (es)
CN (1) CN1128801C (es)
AR (3) AR023920A1 (es)
AT (3) ATE513816T1 (es)
AU (1) AU766618B2 (es)
BR (1) BRPI9915883B8 (es)
CA (1) CA2351709C (es)
CY (3) CY1110501T1 (es)
CZ (3) CZ300373B6 (es)
DE (4) DE69915675D1 (es)
DK (3) DK1135391T3 (es)
EG (1) EG24814A (es)
ES (3) ES2318081T3 (es)
FR (1) FR11C0016I2 (es)
HK (3) HK1039933B (es)
HU (2) HU228589B1 (es)
ID (1) ID29927A (es)
IL (6) IL143232A0 (es)
LT (1) LTC1135391I2 (es)
LU (1) LU91819I2 (es)
MY (1) MY121867A (es)
NO (2) NO319806B1 (es)
NZ (1) NZ511778A (es)
PL (1) PL201283B1 (es)
PT (2) PT1386921E (es)
RU (3) RU2317990C2 (es)
SA (1) SA99200848B1 (es)
SI (3) SI1386917T1 (es)
SK (1) SK286007B6 (es)
TR (1) TR200101567T2 (es)
TW (1) TWI229674B (es)
WO (1) WO2000034283A1 (es)
ZA (1) ZA200104094B (es)

Families Citing this family (124)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI229674B (en) 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
SE9903290D0 (sv) 1999-09-15 1999-09-15 Astra Pharma Prod Novel compounds
SE9904129D0 (sv) 1999-11-15 1999-11-15 Astra Pharma Prod Novel compounds
SE9904377D0 (sv) * 1999-12-01 1999-12-01 Astra Pharma Prod Pharmaceutical combinations
GB0013488D0 (en) * 2000-06-02 2000-07-26 Astrazeneca Ab Chemical compound
TWI290549B (en) * 2000-06-02 2007-12-01 Astrazeneca Ab Process for the preparation of cyclopropyl carboxylic acid ester and derivatives
GB0013407D0 (en) * 2000-06-02 2000-07-26 Astrazeneca Ab Forms of a chemical compound
US7115585B2 (en) 2000-08-21 2006-10-03 Inspire Pharmaceuticals, Inc. Compositions for treating epithelial and retinal tissue diseases
US7018985B1 (en) 2000-08-21 2006-03-28 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
US7452870B2 (en) 2000-08-21 2008-11-18 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with P2Y12 receptor antagonist compound
US7132408B2 (en) 2000-08-21 2006-11-07 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
US6897201B2 (en) 2000-08-21 2005-05-24 Inspire Pharmaceuticals, Inc. Compositions and methods for the treatment of glaucoma or ocular hypertension
SE0101932D0 (sv) * 2001-05-31 2001-05-31 Astrazeneca Ab Pharmaceutical combinations
US7435724B2 (en) 2002-02-27 2008-10-14 Inspire Pharmaceutical, Inc. Degradation-resistant mononucleoside phosphate compounds
MXPA06000675A (es) 2003-07-24 2006-04-19 Astellas Pharma Inc Derivado de quinolona o sal del mismo.
SE0400873D0 (sv) 2004-03-31 2004-03-31 Astrazeneca Ab Chemical process
SE0401001D0 (sv) 2004-03-31 2004-03-31 Astrazeneca Ab Chemical process
WO2007020935A1 (ja) * 2005-08-17 2007-02-22 Ono Pharmaceutical Co., Ltd. Ｐ２ｙ１２受容体および／またはｐ２ｙ１４受容体ブロッカーを含有してなる疼痛治療剤
TWI391378B (zh) 2006-03-16 2013-04-01 Astellas Pharma Inc 喹啉酮衍生物或其製藥學上可被容許之鹽
GB0615620D0 (en) 2006-08-05 2006-09-13 Astrazeneca Ab A process for the preparation of optically active intermediates
WO2008024044A1 (en) * 2006-08-21 2008-02-28 Astrazeneca Ab Compositions, suitable for oral administration, comprising a triazolo [4, 5] pyrimidin derivate
TWI482772B (zh) * 2006-08-21 2015-05-01 Astrazeneca Ab 適合口服且包含三唑并[4,5-d]嘧啶衍生物之組合物
US7566722B2 (en) * 2006-10-31 2009-07-28 Janssen Pharmaceutica, N.V. Triazolopyrimidine derivatives as ADP P2Y12 receptor antagonists
TWI496776B (zh) * 2007-11-15 2015-08-21 Astrazeneca Ab 製備(3aR,4S,6R,6aS)-6-胺基-2,2-二甲基四氫-3aH-環戊并[d][1,3]二氧雜環戊烯-4-醇之純非對映異構性之二苯甲醯-L-酒石酸鹽之方法
UA100864C2 (uk) * 2007-12-03 2013-02-11 Астразенека Аб Спосіб лікування або запобігання аневризмі черевної аорти
TWI389913B (zh) * 2008-09-08 2013-03-21 Lg Life Sciences Ltd 并合雜環化合物
MX2011002505A (es) 2008-09-09 2011-04-07 Astrazeneca Ab Un proceso para preparar [1s-[1-alfa, 2-alfa, 3-beta (1s*, 2r*) 5-beta] ] -3-[7-[2-(3,4-difluorofenil)-ciclopropilamino]-5-(propil tio) 3h-1, 2, 3-triazolo [4,5-d] pirimidin-3-il] -5-(2-hidroxietoxi) ciclopentan-1, 2-diol y sus intermediarios.
WO2010043721A1 (en) 2008-10-17 2010-04-22 Oryzon Genomics, S.A. Oxidase inhibitors and their use
US8993808B2 (en) 2009-01-21 2015-03-31 Oryzon Genomics, S.A. Phenylcyclopropylamine derivatives and their medical use
EP2459564B1 (en) 2009-07-27 2016-09-07 Auspex Pharmaceuticals, Inc. Cyclopropyl modulators of p2y12 receptor
EP2305376A1 (en) 2009-09-23 2011-04-06 Lonza Ltd. Process and catalyst for the catalytic hydrogenation of aromatic and heteroaromatic nitro compounds
US8859555B2 (en) 2009-09-25 2014-10-14 Oryzon Genomics S.A. Lysine Specific Demethylase-1 inhibitors and their use
WO2011042217A1 (en) 2009-10-09 2011-04-14 Oryzon Genomics S.A. Substituted heteroaryl- and aryl- cyclopropylamine acetamides and their use
JP2013512886A (ja) 2009-12-03 2013-04-18 アストラゼネカ アクチボラグ 血小板の凝集阻害剤トリアゾロ［４，５−ｄ］ピリミジン共結晶
EP2515871B1 (en) 2009-12-23 2015-09-23 ratiopharm GmbH Solid pharmaceutical dosage form of ticagrelor
CA2788072A1 (en) 2010-02-16 2011-08-25 Actavis Group Ptc Ehf Improved processes for preparing ticagrelor intermediate, 4,6-dichloro-5-nitro-2-(propylthio)pyrimidine
US9616058B2 (en) 2010-02-24 2017-04-11 Oryzon Genomics, S.A. Potent selective LSD1 inhibitors and dual LSD1/MAO-B inhibitors for antiviral use
US9186337B2 (en) 2010-02-24 2015-11-17 Oryzon Genomics S.A. Lysine demethylase inhibitors for diseases and disorders associated with Hepadnaviridae
RS55348B1 (sr) 2010-04-19 2017-03-31 Oryzon Gnomics S A Inhibitori lizin specifične demetilaze-1 i njihova upotreba
AU2011244023A1 (en) 2010-04-20 2012-10-25 Actavis Group Ptc Ehf Novel process for preparing phenylcyclopropylamine derivatives using novel intermediates
US20130165696A1 (en) 2010-06-30 2013-06-27 Actavis Group Ptc Ehf Novel processes for the preparation of phenylcyclopropylamine derivatives and use thereof for preparing ticagrelor
JP6054868B2 (ja) 2010-07-29 2016-12-27 オリゾン・ジェノミックス・ソシエダッド・アノニマＯｒｙｚｏｎ Ｇｅｎｏｍｉｃｓ Ｓ．Ａ． Ｌｓｄ１のアリールシクロプロピルアミンをベースとしたデメチラーゼ阻害剤およびそれらの医学的使用
US9006449B2 (en) 2010-07-29 2015-04-14 Oryzon Genomics, S.A. Cyclopropylamine derivatives useful as LSD1 inhibitors
WO2012045883A1 (en) 2010-10-08 2012-04-12 Oryzon Genomics S.A. Cyclopropylamine inhibitors of oxidases
WO2012063126A2 (en) 2010-11-09 2012-05-18 Actavis Group Ptc Ehf Improved processes for preparing pure (3ar,4s,6r,6as)-6-amino-2,2-dimethyltetrahdro-3ah-cyclopenta[d] [1,3]-dioxol-4-ol and its key starting material
WO2012072713A2 (en) 2010-11-30 2012-06-07 Oryzon Genomics, S.A. Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae
EP2655341A2 (en) * 2010-12-20 2013-10-30 Actavis Group Ptc Ehf Novel processes for preparing triazolo[4,5-d]pyrimidine derivatives and intermediates thereof
WO2012107498A1 (en) 2011-02-08 2012-08-16 Oryzon Genomics S.A. Lysine demethylase inhibitors for myeloproliferative disorders
CN102653539B (zh) * 2011-03-01 2014-09-17 秦引林 一种抗血小板聚集化合物及其药物组合
EP2694514A2 (en) 2011-04-06 2014-02-12 Teva Pharmaceutical Industries Ltd. New intermediates and processes for preparing ticagrelor
CN102731510B (zh) * 2011-04-07 2015-12-16 博瑞生物医药（苏州）股份有限公司 替卡格雷的衍生物、制备方法及其药物用途
CZ2011229A3 (cs) * 2011-04-19 2012-08-15 Zentiva, K.S. Opticky aktivní soli (3aR,4S,6R,6aS)-6-amino-2,2-dimethyltetrahydro-3aH-cyklopenta-[d][1,3]dioxol-4-olu a zpusob jejich prípravy
DK2707363T3 (en) * 2011-05-13 2015-12-21 Astrazeneca Ab METHOD FOR PREPARING BENZYL - [(3AS, 4R, 6S, 6AR) -6-HYDROXY-2,2-DIMETHYLTETRAHYDRO-3AH-CYCLOPENTA [D] [1,3] -DIOXOL] -4-YL] CARBAMATE AND INTERMEDIATE PROCEDURE
EP2741741A2 (en) * 2011-05-19 2014-06-18 Oryzon Genomics, S.A. Lysine demethylase inhibitors for inflammatory diseases or conditions
US20140296255A1 (en) * 2011-05-19 2014-10-02 Oryzong Genomics, S.A. Lysine demethylase inhibitors for thrombosis and cardiovascular diseases
CA2836394A1 (en) 2011-06-01 2012-12-06 Astrazeneca Ab Novel ticagrelor co - crystal
WO2012172426A1 (en) 2011-06-15 2012-12-20 Actavis Group Ptc Ehf Improved process for preparing cyclopentylamine derivatives and intermediates thereof
CN102924457A (zh) * 2011-08-12 2013-02-13 上海恒瑞医药有限公司 三唑并嘧啶类衍生物、其制备方法及其用途
EP2570405A1 (en) 2011-09-14 2013-03-20 LEK Pharmaceuticals d.d. Synthesis of Triazolopyrimidine Compounds
WO2013037942A1 (en) 2011-09-14 2013-03-21 Lek Pharmaceuticals D.D. Synthesis of triazolopyrimidine compounds
MX356344B (es) 2011-10-20 2018-05-23 Oryzon Genomics Sa Compuestos de (hetero)arilciclopropilamina como inhibidores de lsd1.
PE20141692A1 (es) 2011-10-20 2014-11-08 Oryzon Genomics Sa Compuestos de (hetero) aril ciclopropilamina como inhibidores de lsd1
ES2665546T3 (es) * 2011-10-27 2018-04-26 Lek Pharmaceuticals D.D. Síntesis de compuestos de triazolopirimidina
EP2586773A1 (en) 2011-10-27 2013-05-01 LEK Pharmaceuticals d.d. Synthesis of Triazolopyrimidine Compounds
EP2589587A1 (en) 2011-11-04 2013-05-08 Chemo Ibérica, S.A. Synthesis of nitrogen substituted cyclopropanes
EP2785716A1 (en) 2011-11-30 2014-10-08 Actavis Group PTC EHF Novel crystalline form of ticagrelor and process for the preparation thereof
EP2794575B1 (en) 2011-12-23 2018-12-05 LEK Pharmaceuticals d.d. Synthesis of triazolopyrimidine compounds
EP2607355A1 (en) * 2011-12-23 2013-06-26 LEK Pharmaceuticals d.d. Synthesis of triazolopyrimidine compounds
EP2628721A1 (en) 2012-02-20 2013-08-21 LEK Pharmaceuticals d.d. Synthesis of 2-(3,4-difluorophenyl)cyclopropanecarboxylic acid
CN104603098B (zh) 2012-03-30 2016-06-29 桑多斯股份公司 2-(3,4-二氟苯基)环丙胺衍生物和盐的合成
EP2644590A1 (en) 2012-03-30 2013-10-02 LEK Pharmaceuticals d.d. Synthesis of 2-(3,4-difluorophenyl)cyclopropanamine derivatives and salts
WO2013150495A2 (en) 2012-04-05 2013-10-10 Dr. Reddy's Laboratories Limited Preparation of ticagrelor
WO2013163892A1 (en) * 2012-05-02 2013-11-07 Sunshine Lake Pharma Co., Ltd. Novel triazolo pyrimidine compounds and a process of preparation thereof
CN102659815B (zh) * 2012-05-04 2013-07-17 开原亨泰制药股份有限公司 一种制备选择性抗凝血药替卡格雷及其中间体的方法
EP2666771A1 (en) 2012-05-24 2013-11-27 LEK Pharmaceuticals d.d. Synthesis of Aminocyclopentanetriol Derivatives
ITMI20121142A1 (it) * 2012-06-28 2013-12-29 Chemo Iberica Sa Processo chemoenzimatico per la produzione di fenil ciclopropilammine
BR112014032085A2 (pt) 2012-06-29 2017-06-27 Zentiva Ks solvato de ticagrelor, processos para a preparação de um solvato e para a preparação de um cocristal, cocristal de ticagrelor, e, usos de um solvato e de um cocristal
US9284320B2 (en) 2012-07-04 2016-03-15 Lek Pharmaceuticals D.D. Ticagrelor adducts with divalent metal salts
CN103626743B (zh) * 2012-08-23 2018-06-08 广东东阳光药业有限公司 替卡格雷的新型中间体及其制备方法
CN102875537A (zh) * 2012-09-10 2013-01-16 常州制药厂有限公司 一种新的抗血栓药物的制备方法
CZ2012705A3 (cs) 2012-10-16 2014-04-23 Zentiva, K.S. Pevná orální farmaceutická formulace obsahující ticagrelor
WO2014083139A1 (en) 2012-11-29 2014-06-05 Actavis Group Ptc Ehf Novel amorphous form of ticagrelor
WO2014102830A1 (en) 2012-12-31 2014-07-03 Megafine Pharma (P) Ltd. A process for preparation of ticagrelor and intermediates thereof
CN104045620B (zh) * 2013-03-12 2017-05-10 博瑞生物医药（苏州）股份有限公司 一种替卡格雷中间体的制备方法
CZ307217B6 (cs) 2013-03-14 2018-04-04 Zentiva, K.S. Zlepšený způsob výroby a nové intermediáty syntézy ticagreloru
IN2013MU01111A (es) * 2013-03-25 2015-05-01 Glenmark Generics Ltd
ITMI20130487A1 (it) 2013-03-29 2014-09-30 Chemo Res S L Alchilazione selettiva di ciclopentilalcoli
CN107573333B (zh) * 2013-04-10 2019-10-18 江苏恒瑞医药股份有限公司 替格瑞洛的中间体及其制备方法和替格瑞洛的制备方法
EP2813216A1 (en) 2013-06-10 2014-12-17 Zentiva, a.s. Stabilized amorphous ticagrelor
WO2014170026A1 (en) 2013-04-18 2014-10-23 Zentiva, K.S. Stabilized amorphous ticagrelor
CN104230818B (zh) * 2013-06-06 2018-01-12 郝聪梅 替卡格雷中间体的改进制备方法
EP2816043A1 (en) 2013-06-21 2014-12-24 LEK Pharmaceuticals d.d. Spherical ticagrelor particles
WO2014206187A1 (zh) 2013-06-24 2014-12-31 苏州明锐医药科技有限公司 替卡格雷及其中间体的制备方法
CN104250251B (zh) * 2013-06-25 2017-05-17 上海京新生物医药有限公司 一种替格瑞洛的制备方法
WO2015001489A1 (en) 2013-07-01 2015-01-08 Ranbaxy Laboratories Limited Pharmaceutical compositions of ticagrelor
CZ2013866A3 (cs) 2013-11-08 2015-05-20 Zentiva, K.S. Způsob výroby a nová krystalická forma intermediátu syntézy ticagreloru
WO2015110952A1 (en) 2014-01-21 2015-07-30 Wockhardt Limited Solid oral pharmaceutical compositions comprising ticagrelor or salt thereof
CN103992323B (zh) * 2014-04-18 2017-03-29 南通常佑药业科技有限公司 一种替格瑞洛的制备方法
WO2015162630A1 (en) 2014-04-25 2015-10-29 Anlon Chemical Research Organization Novel processes for preparing triazolo [4,5-d]- pyrimidines, including ticagrelor, vianew intermediates and new route of synthesis.
DE102014108210A1 (de) 2014-06-11 2015-12-17 Dietrich Gulba Rodentizid
US10011605B2 (en) 2014-06-18 2018-07-03 Flamma Spa Process for the preparation of triazolo[4,5-D] pyrimidine cyclopentane compounds
CN105272985B (zh) * 2014-06-24 2017-11-21 珠海联邦制药股份有限公司 三唑并[4,5‑d]嘧啶化合物及其合成方法、用途、组合物
WO2016001851A1 (en) * 2014-07-02 2016-01-07 Dr. Reddy's Laboratories Limited Preparation of ticagrelor
US9982061B2 (en) 2014-10-01 2018-05-29 Medimmune Limited Antibodies to ticagrelor and methods of use
WO2016116942A1 (en) 2015-01-20 2016-07-28 Anlon Chemical Research Organization Novel pharmaceutical compounds comprising ticagrelor with salts of aspirin
CN105985346B (zh) * 2015-03-06 2019-10-18 苏州朗科生物技术股份有限公司 一种新的替格瑞洛化合物制备方法及其中间体化合物
US9789087B2 (en) 2015-08-03 2017-10-17 Thomas Jefferson University PAR4 inhibitor therapy for patients with PAR4 polymorphism
CN105237540B (zh) * 2015-09-21 2017-10-03 南京正大天晴制药有限公司 一种替格瑞洛有关物质的制备方法、检测方法及用途
WO2017118633A1 (en) 2016-01-05 2017-07-13 Amneal Pharmaceuticals Company Gmbh Crystalline form of ticagrelor
TR201601835A2 (tr) 2016-02-12 2017-08-21 Ali Raif Ilac Sanayi Ve Ticaret Anonim Sirketi Ti̇kagrelor i̇çeren formülasyonlar i̇çi̇n üreti̇m yöntemi̇
US20170296666A1 (en) 2016-04-18 2017-10-19 Amneal Pharmaceuticals Company Gmbh Stable Pharmaceutical Composition Of Amorphous Ticagrelor
CN107595789B (zh) 2016-04-21 2021-01-15 阿斯利康(瑞典)有限公司 口腔崩解片
SG11201901619WA (en) * 2016-08-26 2019-03-28 Mitsubishi Tanabe Pharma Corp Bicyclic nitrogenated heterocyclic compound
DK3292867T3 (da) * 2016-09-09 2019-07-22 Univ Liege Ny brug af triazol(4,5-d)pyrimidinderivater til brug i forebyggelsen og behandlingen af bakteriel infektion
US10905691B2 (en) 2016-09-09 2021-02-02 Université de Liège Use of triazolo(4,5-d)pyrimidine derivatives for prevention and treatment of bacterial infection
CN107814772A (zh) * 2017-11-24 2018-03-20 常州沃腾化工科技有限公司 4,6‑二氯‑5‑氨基‑2‑丙硫基嘧啶酯的精制方法
EP3527571A1 (en) * 2018-02-14 2019-08-21 Université de Liège Pyrimidine derivatives for prevention and treatment of bacterial infection
EA202190328A1 (ru) 2018-07-27 2021-07-01 КРКА, д.д., НОВО МЕСТО Фармацевтическая композиция, содержащая тикагрелор
CN109761785A (zh) * 2019-02-16 2019-05-17 安徽诺全药业有限公司 一种(1r，2r）-2-(3,4-二氟苯基)环丙烷羧酸的合成方法
GB201910656D0 (en) * 2019-07-25 2019-09-11 Univ Liege New use of triazolo(4,5-d)Pyrimidine deerivatives
EP3919497A1 (en) 2020-06-04 2021-12-08 Zaklady Farmaceutyczne Polpharma S.A. Process for the preparation of ticagrelor
CN112876485A (zh) * 2021-01-25 2021-06-01 郭丽伟 一种用于治疗子宫平滑肌高频率强直性收缩相关疾病的化合物
EP4070658A1 (de) 2021-04-06 2022-10-12 BIORoxx GmbH Verwendung von blutgerinnungshemmenden verbindungen als rodentizide
CN117003756A (zh) * 2022-05-04 2023-11-07 华东师范大学 芳香稠环化合物作为trek-1激活剂的用途、包含其的药物组合物、镇痛剂

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3106578A (en) 1960-09-16 1963-10-08 Smith Kline French Lab Nu-phenethyl-2-phenylcyclopropylamine derivatives
SE329623B (es) 1967-06-08 1970-10-19 C F Boehringer Soehne Gmbh
DE1670265A1 (de) 1967-08-25 1971-01-28 Boehringer Mannheim Gmbh 2-Amino-Adenosinderivate und Verfahren zu deren Herstellung
CH558137A (de) 1971-05-17 1975-01-31 Ciba Geigy Ag Mittel zur beeinflussung des pflanzenwachstums.
US4016204A (en) 1975-10-31 1977-04-05 Nelson Research & Development Company Method of synthesis of trans-2-phenylcyclopropylamine
US4543255A (en) 1984-05-10 1985-09-24 Southern Research Institute Carbocyclic analogs of purine 2'-deoxyribofuranosides
US4742064A (en) 1985-09-10 1988-05-03 Regents Of The University Of Minnesota Antiviral carbocyclic analogs of xylofuranosylpurines
CH679152A5 (es) 1988-01-20 1991-12-31 Univ Minnesota
WO1990006671A2 (en) 1988-12-12 1990-06-28 Palese Peter M Methods and compositions for the prophylaxis and treatment of hepatitis b virus infections
US5110933A (en) 1989-11-13 1992-05-05 Board Of Regents Of Oklahoma State University Salts of 3-azabicyclo[3.3.1]nonanes as antiarrhythmic agents, and precursors thereof
US5652366A (en) 1990-09-25 1997-07-29 Rhone-Poulenc Rorer Pharmaceuticals Inc. DI (1R)-(-)camphosulfonic acid) salt, preparation thereof and use thereof
AU665184B2 (en) 1991-01-23 1995-12-21 Gensia, Inc. Adenosine kinase inhibitors
CA2107667A1 (en) 1991-04-06 1992-10-07 Anthony Howard Ingall Atp analogues
EP0521463A3 (en) 1991-07-04 1993-04-14 Hoechst Aktiengesellschaft Substituted cyclic cycloalkyltriols, process, intermediates for their preparation and their use as antiviral and antiparasitic agents
FI101150B (fi) 1991-09-09 1998-04-30 Sankyo Co Menetelmä lääkeaineina käyttökelpoisten tetrahydrotienopyridiinin johd annaisten valmistamiseksi
US5817660A (en) 1991-12-06 1998-10-06 Hoechst Marion Roussel, Inc. Trans cyclopentanyl purine analogs useful as immunosuppressants
US5338725A (en) 1992-06-30 1994-08-16 The Research Foundation Of The State University Of New York Anti-aggregatory agents for platelets
IL108523A0 (en) 1993-02-03 1994-05-30 Gensia Inc Pharmaceutical compositions containing adenosine kinase inhibitors for preventing or treating conditions involving inflammatory responses and pain
PL175623B1 (pl) 1993-02-10 1999-01-29 Astra Pharma Prod N-alkilo-2-podstawione analogi ATP, sposób ich wytwarzania i kompozycja farmaceutyczna je zawierająca
US5688774A (en) 1993-07-13 1997-11-18 The United States Of America As Represented By The Department Of Health And Human Services A3 adenosine receptor agonists
US5620676A (en) 1994-03-08 1997-04-15 The United States Of America As Represented By The Department Of Health And Human Services Biologically active ATP analogs
US5831099A (en) 1995-03-10 1998-11-03 The United States Of America As Represented By The Secretary Of The Army Compounds of 1,5-disubstituted-3,7 diaza bicyclo 3.3.0! octanes and products containing the same
US5712258A (en) 1995-03-23 1998-01-27 The Trustees Of The University Of Pennsylvania Inotropic ADP and ATP analogues and their pharmaceutical compositions
US6143749A (en) 1995-06-07 2000-11-07 Abbott Laboratories Heterocyclic substituted cyclopentane compounds
PL182680B1 (pl) 1995-07-11 2002-02-28 Astrazeneca Ab Nowe inhibitory skupiania się płytek krwi
AU6754296A (en) 1995-09-01 1997-03-27 Hokuriku Seiyaku Co. Ltd Crystal of hydrate and process for preparation thereof
ATE270331T1 (de) 1995-11-21 2004-07-15 Euroscreen Sa Rezeptor und dafür kodierendes nukleinsäuremolekül
US5948437A (en) 1996-05-23 1999-09-07 Zeneca Limited Pharmaceutical compositions using thiazepine
ATE213245T1 (de) * 1996-12-20 2002-02-15 Triazolo(4,5-d)pyrimidinyl-derivate und ihre verwendung als medikamente
JPH10258654A (ja) 1997-03-18 1998-09-29 Delta Tsuuring:Kk リクライニングシート
SE9702772D0 (sv) * 1997-07-22 1997-07-22 Astra Pharma Prod Novel compounds
SE9702775D0 (sv) 1997-07-22 1997-07-22 Astra Pharma Prod Novel compounds
TW530058B (en) * 1997-07-22 2003-05-01 Astra Pharma Prod Triazolo [4,5-d]pyrimidine compounos and their use and process for preparation
SE9702773D0 (sv) 1997-07-22 1997-07-22 Astra Pharma Prod Novel compounds
SE9704709D0 (sv) 1997-12-17 1997-12-17 Astra Ab Pharmaceutically active compounds
TWI229674B (en) 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
EP1063231B1 (en) 1999-06-21 2005-05-11 Yamamoto Chemicals, Inc. Polymethine compounds, method of producing the same, and use thereof
SE9903759D0 (sv) 1999-10-18 1999-10-18 Astra Ab Pharmaceutically active compounds
DK1230241T3 (da) 1999-11-12 2007-06-04 Biogen Idec Inc Adenosinreceptorantagonister og fremgangsmåder til fremstilling og anvendelse af samme
GB0013407D0 (en) 2000-06-02 2000-07-26 Astrazeneca Ab Forms of a chemical compound
US7040429B2 (en) 2001-10-10 2006-05-09 Invacare Corporation Wheelchair suspension
CA2469246A1 (en) 2001-12-21 2003-07-03 Pfizer Products Inc. Directly compressible formulations of azithromycin
TWI482772B (zh) 2006-08-21 2015-05-01 Astrazeneca Ab 適合口服且包含三唑并[4,5-d]嘧啶衍生物之組合物
MX2011002505A (es) 2008-09-09 2011-04-07 Astrazeneca Ab Un proceso para preparar [1s-[1-alfa, 2-alfa, 3-beta (1s*, 2r*) 5-beta] ] -3-[7-[2-(3,4-difluorofenil)-ciclopropilamino]-5-(propil tio) 3h-1, 2, 3-triazolo [4,5-d] pirimidin-3-il] -5-(2-hidroxietoxi) ciclopentan-1, 2-diol y sus intermediarios.
CA2788072A1 (en) 2010-02-16 2011-08-25 Actavis Group Ptc Ehf Improved processes for preparing ticagrelor intermediate, 4,6-dichloro-5-nitro-2-(propylthio)pyrimidine
US20130165696A1 (en) 2010-06-30 2013-06-27 Actavis Group Ptc Ehf Novel processes for the preparation of phenylcyclopropylamine derivatives and use thereof for preparing ticagrelor
EP2655341A2 (en) 2010-12-20 2013-10-30 Actavis Group Ptc Ehf Novel processes for preparing triazolo[4,5-d]pyrimidine derivatives and intermediates thereof
EP2694514A2 (en) 2011-04-06 2014-02-12 Teva Pharmaceutical Industries Ltd. New intermediates and processes for preparing ticagrelor
WO2012172426A1 (en) 2011-06-15 2012-12-20 Actavis Group Ptc Ehf Improved process for preparing cyclopentylamine derivatives and intermediates thereof
EP2785716A1 (en) 2011-11-30 2014-10-08 Actavis Group PTC EHF Novel crystalline form of ticagrelor and process for the preparation thereof
WO2013150495A2 (en) 2012-04-05 2013-10-10 Dr. Reddy's Laboratories Limited Preparation of ticagrelor
WO2014083139A1 (en) 2012-11-29 2014-06-05 Actavis Group Ptc Ehf Novel amorphous form of ticagrelor
WO2014102830A1 (en) 2012-12-31 2014-07-03 Megafine Pharma (P) Ltd. A process for preparation of ticagrelor and intermediates thereof
WO2014118808A2 (en) 2013-02-04 2014-08-07 Hetero Research Foundation Ticagrelor solid dispersion
CN107573333B (zh) 2013-04-10 2019-10-18 江苏恒瑞医药股份有限公司 替格瑞洛的中间体及其制备方法和替格瑞洛的制备方法
EP3004113A2 (en) 2013-06-04 2016-04-13 Dr. Reddy's Laboratories Ltd. Preparation of ticagrelor
WO2016001851A1 (en) 2014-07-02 2016-01-07 Dr. Reddy's Laboratories Limited Preparation of ticagrelor
CN112402432A (zh) 2015-01-27 2021-02-26 阿斯利康(瑞典)有限公司 治疗或预防具有心肌梗塞病史的患者的动脉粥样硬化血栓形成事件的方法

Also Published As

Publication number Publication date
CY2011005I2 (el) 2014-04-09
HUS1300048I1 (hu) 2017-03-28
PT1135391E (pt) 2004-07-30
AU766618B2 (en) 2003-10-23
NO319806B1 (no) 2005-09-19
SA99200848B1 (ar) 2006-11-04
CZ300373B6 (cs) 2009-05-06
BR9915883A (pt) 2001-08-21
ATE513816T1 (de) 2011-07-15
EP1386921A1 (en) 2004-02-04
IL198040A0 (en) 2009-12-24
US20030144305A1 (en) 2003-07-31
US20140296258A1 (en) 2014-10-02
BRPI9915883B8 (pt) 2021-05-25
DE69915675T2 (de) 2005-02-17
IL169013A (en) 2015-10-29
ZA200104094B (en) 2002-08-19
DE69915675T4 (de) 2012-08-30
ES2216623T3 (es) 2004-10-16
ES2318081T3 (es) 2009-05-01
US20120165348A1 (en) 2012-06-28
EP1135391A1 (en) 2001-09-26
HK1061684A1 (en) 2004-09-30
KR100764417B1 (ko) 2007-10-05
RU2007133926A (ru) 2009-03-20
AU2016500A (en) 2000-06-26
DE69915675D1 (de) 2004-04-22
EG24814A (en) 2010-09-21
US20130072503A1 (en) 2013-03-21
IL143232A (en) 2008-12-29
ES2366902T3 (es) 2011-10-26
JP2008266345A (ja) 2008-11-06
LTPA2011004I1 (lt) 2022-04-11
LU91819I2 (fr) 2011-08-01
HK1039933A1 (en) 2002-05-17
RU2012121883A (ru) 2013-11-27
SI1386917T1 (sl) 2011-09-30
SI1386921T1 (sl) 2009-04-30
EP1386909A1 (en) 2004-02-04
KR20010081054A (ko) 2001-08-25
SK7492001A3 (en) 2002-01-07
DK1386921T3 (da) 2009-03-23
SI1135391T1 (en) 2004-08-31
US6974868B2 (en) 2005-12-13
EP2322513A2 (en) 2011-05-18
DE69940171D1 (de) 2009-02-05
NO2011007I2 (no) 2012-07-09
KR20060091056A (ko) 2006-08-17
IL210398A0 (en) 2011-03-31
EP1386917B1 (en) 2011-06-22
IL143232A0 (en) 2002-04-21
AR072756A2 (es) 2010-09-22
US20060025590A1 (en) 2006-02-02
CZ300280B6 (cs) 2009-04-08
IL183969A0 (en) 2009-02-11
US20100069408A1 (en) 2010-03-18
HK1061246A1 (en) 2004-09-10
LTC1135391I2 (lt) 2022-04-11
DK1135391T3 (da) 2004-06-28
FR11C0016I1 (es) 2011-07-08
HU228589B1 (en) 2013-04-29
EP1386921B1 (en) 2008-12-24
NO2011007I1 (no) 2011-06-06
PT1386921E (pt) 2009-02-23
AR023920A1 (es) 2002-09-04
JP2007084551A (ja) 2007-04-05
RU2593201C2 (ru) 2016-08-10
US20070265282A1 (en) 2007-11-15
JP2002531567A (ja) 2002-09-24
TWI229674B (en) 2005-03-21
KR100742924B1 (ko) 2007-07-25
EP1135391B1 (en) 2004-03-17
DE122011100004I1 (de) 2011-09-08
JP5415383B2 (ja) 2014-02-12
ATE261970T1 (de) 2004-04-15
USRE46276E1 (en) 2017-01-17
RU2317990C2 (ru) 2008-02-27
NO20012725L (no) 2001-07-31
FR11C0016I2 (fr) 2012-03-16
CY2011005I1 (el) 2014-04-09
CA2351709A1 (en) 2000-06-15
ATE418547T1 (de) 2009-01-15
DK1386917T3 (da) 2011-08-29
HK1039933B (zh) 2004-10-08
NZ511778A (en) 2003-10-31
KR100776484B1 (ko) 2007-11-28
CY1111759T1 (el) 2015-10-07
PL201283B1 (pl) 2009-03-31
EP2322513A3 (en) 2011-08-24
NO20012725D0 (no) 2001-06-01
JP4202607B2 (ja) 2008-12-24
KR20070007971A (ko) 2007-01-16
IL183969A (en) 2011-03-31
MY121867A (en) 2006-02-28
WO2000034283A1 (en) 2000-06-15
HUP0105081A3 (en) 2004-11-29
IL198040A (en) 2015-06-30
TR200101567T2 (tr) 2001-12-21
US20150152111A1 (en) 2015-06-04
JP2011016831A (ja) 2011-01-27
KR100822602B1 (ko) 2008-04-16
CZ20011962A3 (cs) 2001-11-14
PL348724A1 (en) 2002-06-03
CY1110501T1 (el) 2015-04-29
EP1386917A1 (en) 2004-02-04
AR058967A2 (es) 2008-03-05
JP5043749B2 (ja) 2012-10-10
CA2351709C (en) 2010-04-06
HUP0105081A2 (hu) 2002-05-29
US7250419B2 (en) 2007-07-31
CN1128801C (zh) 2003-11-26
BRPI9915883B1 (pt) 2015-08-18
US6525060B1 (en) 2003-02-25
US20080214812A1 (en) 2008-09-04
SK286007B6 (sk) 2008-01-07
US20130109702A1 (en) 2013-05-02
KR20070086540A (ko) 2007-08-27
CN1334816A (zh) 2002-02-06
CZ295234B6 (cs) 2005-06-15

Similar Documents

Publication Publication Date Title
ID29927A (id) Senyawa-senyawa triazolo (4,5-d) pirimidin baru
ATE270673T1 (de) Pyrrolo(2,3-d)pyrimidin-verbindungen
DE69916833D1 (de) Pyrrolo(2,3-d)pyrimidin-verbindungen
ID27127A (id) SENYAWA-SENYAWA TRIAZOLO (4,5-d) PIRIMIDINA YANG BARU
IS2236B (is) Tríasóló (4,5-d)pýrimídínafleiður sem lyf gegn segamyndun
NO20022738L (no) Pyrrolo(2,3-d)pyrimidinforbindelser
ATE269333T1 (de) 2-pyridinyl-6,7,8,9-tetrahydropyrimido(1,2- a)pyrimidin-4-on- und 7-pyridinyl-2,3- dihydroimidazo(1,2-a)pyrimidin-5 1honderivate